Assuming you're right, I think, it will be a critical part of the baseline standard of care, which is huge, and that for some segment, it will be the baseline equivalent of a cure, but there is never any certainty with a cancer as hard to beat as GBM, when even there is no sign of the cancer in the body, that cells might not find a way to come back. But, with combination therapies, I think that the apparent cure, whether permanent or not, will become more clear, at least for some range of the patients. Eventually the scientists will figure out the other patients as well.
I believe this platform will be a critical piece of a longer end game and necessary platform for extending the immunotherapy concept, and making a broad range of immunotherapies more efficacious.
News 
Market Data 
Discover 
